Levels of circulating glucose are tightly regulated. To identify new loci influencing glycemic traits, we performed meta-analyses of 21 genome-wide association studies informative for fasting glucose, fasting insulin and indices of beta-cell function (HOMA-B) and insulin resistance (HOMA-IR) in up to 46,186 nondiabetic participants. Follow-up of 25 loci in up to 76,558 additional subjects identified 16 loci associated with fasting glucose and HOMA-B and two loci associated with fasting insulin and HOMA-IR. These include nine loci newly associated with fasting glucose (in or near ADCY5, MADD, ADRA2A, CRY2, FADS1, GLIS3, SLC2A2, PROX1 and C2CD4B ) and one influencing fasting insulin and HOMA-IR (near IGF1). We also demonstrated association of ADCY5, PROX1, GCK, GCKR and DGKB-TMEM195 with type 2 diabetes. Within these loci, likely biological candidate genes influence signal transduction, cell proliferation, development, glucose-sensing and circadian regulation. Our results demonstrate that genetic studies of glycemic traits can identify type 2 diabetes risk loci, as well as loci containing gene variants that are associated with a modest elevation in glucose levels but are not associated with overt diabetes.
A r t i c l e s
Impaired beta-cell function and insulin resistance are key determinants of type 2 diabetes (T2D). Hyperglycemia in the fasting state is one of the criteria that defines T2D 1 , it can predict definitive clinical endpoints in nondiabetic individuals 2, 3 and, when corrected in subjects with T2D, may help prevent microvascular 4, 5 and long-term macrovascular 6, 7 complications. To date, there are nearly 20 published loci reproducibly associated with T2D 8 ; most of these are also associated with decreased insulin secretion 9 due to defective beta-cell function or beta-cell mass. Association studies for diabetes-related quantitative traits in participants without diabetes have also identified loci influencing fasting glucose levels, whose effects appear to be mediated by impairment of the glucose-sensing machinery in beta cells [10] [11] [12] [13] [14] [15] [16] [17] .
We recently formed the Meta-Analyses of Glucose and Insulinrelated traits Consortium (MAGIC) to conduct large-scale metaanalyses of genome-wide data for continuous diabetes-related traits in participants without diabetes 15 . We aimed to identify additional loci that influence glycemic traits in individuals free of diabetes and investigate their impact on related metabolic phenotypes. We were also interested in understanding variation in the physiological range of glycemia and evaluating the extent to which the same variants influence pathological fasting glucose variation and T2D risk. The initial MAGIC collaboration identified the fasting glucose-and T2D-associated locus in MTNR1B 15 , which was also reported by others 16, 17 ; this finding demonstrated that studies of continuous glycemic phenotypes in nondiabetic individuals can complement the genetic analyses of diabetes as a dichotomous trait and can improve our understanding of the mechanisms involved in beta-cell function and glucose homeostasis. Here, we extend our previous approach by performing meta-analyses of ~2.5 million directly genotyped or imputed autosomal SNPs from 21 genome-wide association studies (GWAS). These 21 cohorts include up to 46,186 nondiabetic participants of European descent informative for fasting glucose and 20 GWAS including up to 38,238 nondiabetic individuals informative for fasting insulin, as well as the surrogate estimates of beta-cell function (HOMA-B) and insulin resistance (HOMA-IR) derived from fasting variables by homeostasis model assessment 18 . Follow-up of 25 lead SNPs in up to 76,558 additional individuals of European ancestry identified nine new genome-wide significant associations (empirically determined as P < 5 × 10 −8 ) 19 with fasting glucose and one with fasting insulin and HOMA-IR. Five of these loci also demonstrated genome-wide significant evidence for association between the glucose-raising allele and T2D risk in up to 40,655 cases and 87,022 nondiabetic controls.
The wealth of loci newly discovered to be associated with fasting glucose and HOMA-B contrasts with the single new locus identified for fasting insulin and HOMA-IR and suggests that there is a different genetic architecture for beta-cell function and insulin resistance. Furthermore, our data support the hypothesis that not all loci that influence glycemia within the physiological range are also associated with pathological levels of glucose and T2D risk.
RESULTS

Genome-wide association meta-analysis of glycemic traits
We conducted a two-stage association study in individuals of European descent (Online Methods, Supplementary Fig. 1 and Supplementary  Table 1a ,b). Because we sought to identify variants that influence fasting glucose in the unaffected population, hyperglycemia in the diabetic range exerts deleterious effects on beta-cell function 20, 21 and treatment can confound glucose and insulin measurements, we excluded individuals with known diabetes, those on anti-diabetic treatment, and those with fasting glucose ≥7 mmol/l. We combined data from 21 stage 1 discovery GWAS for fasting glucose (n = 46,186) and 20 GWAS for fasting insulin (n = 38,238), HOMA-B (n = 36, 466) and HOMA-IR (n = 37,037) and analyzed associations for ~2.5 million autosomal SNPs directly genotyped and imputed 22, 23 from HapMap CEU sample data, assuming an additive genetic effect for each of the 4 traits.
Inverse variance-weighted meta-analyses revealed 12 independent loci associated with fasting glucose and/or HOMA-B at genome-wide significance levels ( Table 1, Supplementary Table 2 and Supplementary Fig. 2a,b) . These included five newly discovered associations for loci in or near ADCY5, MADD, ADRA2A, CRY2 and FADS1 ( Table 1 and Fig. 1a-j) , four previously reported fasting glucose-associated loci in or near GCK, GCKR, G6PC2 and MTNR1B, the recently reported 24 locus in DGKB-TMEM195, and two loci in the T2D susceptibility genes TCF7L2 (rs4506565, r 2 = 0.92 with the previously reported SNP rs7903146) and SLC30A8 (rs11558471, r 2 = 0.96 with the previously reported SNP rs13266634). Seven additional loci had reproducible evidence for association with fasting glucose and/or HOMA-B across studies at the arbitrary summary threshold of P < 2 × 10 −5 , chosen to prioritize SNPs for follow-up ( Table 1 and Supplementary  Table 2 ). After excluding SNPs within the four previously discovered genome-wide significant fasting glucose loci in GCK, GCKR, G6PC2 and MTNR1B, we still observed an excess of small P values compared to the distribution expected under the null hypothesis ( Fig. 2a,b ), suggesting that some of these additional loci are likely to represent new fasting glucose-and/or HOMA-B-associated loci that merit additional investigation.
Stage 1 analyses of fasting insulin and HOMA-IR revealed no loci that reached genome-wide significance, but there were six loci with consistent evidence for association across study samples at P < 2 × 10 −5 ( Table 1, Supplementary Table 2 and Supplementary Fig. 2c,d) .
Comparison of the observed P values with the distribution expected under the null hypothesis showed an excess of small P values that warrant further investigation ( Fig. 2c,d) . Directly genotyped and imputed SNPs were tested for association with fasting glucose, fasting insulin and homeostasis model assessment of beta-cell function (HOMA-B) and insulin resistance (HOMA-IR). Twenty-one discovery cohorts with genome-wide data were meta-analyzed (stage 1 discovery), and 25 SNPs were promoted for replication of the same trait in a set of 33 additional cohorts with in silico (n = 7) or de novo (n = 26) genotype data (n = 31 for fasting insulin, HOMA-B and HOMA-IR; for stage 2 replication P values and effect sizes, see table 2). A joint analysis was then performed (global). Heterogeneity in the discovery sample was assessed using the I 2 index 48 . Replication was not attempted for SNPs in two known T2D-associated genes (SLC30A8 and TCF7L2) that achieved genome-wide significance for fasting glucose in stage 1. Freq denotes the allele frequency of the glucose-raising allele. n = sample size. Note that the previously reported GCKR SNP has associations with glucose-related and insulin-related traits.
A r t i c l e s
We further conducted a global meta-analysis of cohort results adjusted for body mass index (BMI) to test whether these diabetesrelated quantitative trait associations may be mediated by associations with adiposity. The adjustment for BMI did not materially affect the strength of the associations with any of the traits (data not shown).
Effect size estimates for genome-wide significant loci
We restricted our effect size estimates ( Table 2 and Supplementary  Table 2 ) to the stage 2 replication samples (up to n = 76,558) to avoid inflation introduced by the discovery cohorts (the so-called 'winner's curse' 26 ). The previously identified loci in G6PC2, MTNR1B and GCK showed the largest effects on fasting glucose (0.075, 0.067 and 0.062 mmol/l per allele, respectively), with the remaining loci examined showing smaller effects (0.008 to 0.030 mmol/l per allele; Table 2 ). The proportion of variance in fasting glucose explained by the 14 fasting glucose-associated loci with replication data (that is, all fasting glucose loci except for those on TCF7L2 and SLC30A8) ranged from 3.2%-4.4% in the six replication studies providing this information. Because results from our largest unselected community-based cohort (Framingham) were on the lower bound of these estimates (3.2%), we felt reassured that the winner's curse was not a major concern in this instance and selected the Framingham cohort to estimate the proportion of heritability explained and the genotype score. With a heritability estimate of 30.4% in the Framingham cohort, these 14 loci explain a substantial proportion (~10%) of the inherited variation in fasting glucose. Given the possibility that these same loci harbor additional independent variants (for example, those due to low-frequency alleles not captured by this analysis) that also influence fasting glucose 27 , this estimate of the heritability attributable to these loci is likely to be conservative.
We estimated the combined impact of the 16 loci associated with fasting glucose (the 14 loci included in the effect size estimates plus those on TCF7L2 and SLC30A8) in some of the largest cohorts (Framingham, the Northern Finland Birth Cohort (NFBC) of 1966 and the Atherosclerosis Risk in Communities (ARIC) study) by constructing a genotype score equal to the sum of the expected number of risk alleles at each SNP weighted by their effect sizes (see Online Methods). Fasting glucose levels were higher in individuals with higher genotype scores ( Fig. 3) , with mean differences of ~0.4 mmol/l (5.93 versus 5.51 mmol/l in NFBC 1966; 5.36 versus 5.03 mmol/l in In each panel, the stage 1 discovery SNP taken forward to stage 2 replication is represented by a blue diamond (with global meta-analysis P value), with its stage 1 discovery P value denoted by a red diamond. Estimated recombination rates (taken from HapMap) are plotted to reflect the local LD structure around the associated SNPs and their correlated proxies (according to a whiteto-red scale from r 2 = 0 to 1, based on pairwise r 2 values from HapMap CEU). Gene annotations were taken from the UCSC genome browser.
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A r t i c l e s
Framingham; 5.70 versus 5.29 mmol/l in ARIC) when comparing individuals with a score of 23 or higher (5.6% of the sample) to those with a score of 12 or lower (2.9% of the sample). The 0.4 mmol/l (7.2 mg/dl) difference between the two tails of the distribution of risk score in the population (top 5.6% compared to the bottom 2.9%) is of clinical relevance, as it represents a shift of approximately 25 centile points in the distribution of fasting glucose. Prospective evidence has shown that a difference of this magnitude in fasting glucose is associated with a relative risk of 1.54-1.73 for future T2D, accounting for other risk factors 28 . The impact of individual SNPs on fasting glucose in the combined discovery and replication samples is shown in Supplementary Figure 3 .
We also analyzed data from 1,602 self-reported white European children aged 5.9-17.2 from two studies. Though directionally consistent with observations in adults, some effect size estimates in these children were of smaller magnitude (data not shown). As in adults, the largest effect sizes were observed for risk alleles in GCK (b = 0.085, P = 1.2 × 10 −5 , n = 1,602), G6PC2 (b = 0.062, P = 1.9 × 10 −4 , n = 1,582) and MTNR1B (b = 0.033, P = 0.058, n = 1,309).
Impact of reproducibly associated loci on additional glycemic traits
We sought to investigate all 17 loci associated with fasting glucose, HOMA-B, fasting insulin or HOMA-IR at genome-wide significance for their effects on other continuous glycemic traits. Whereas most of the 16 loci associated with fasting glucose are also strongly associated with HOMA-B (Tables 1 and 2), the associations between fasting glucose loci and fasting insulin were weak at best; GCKR is the only locus reaching genome-wide significant associations for both fasting glucose and fasting insulin or HOMA-IR, with the glucose-raising C allele being associated with increased fasting insulin (global P = 3.6 × 10 −20 ) and HOMA-IR (global P = 3.0 × 10 −24 ). These patterns are consistent with the gross trait correlations obtained in Framingham for fasting glucose and HOMA-B (r = −0.43) and for fasting glucose and fasting insulin (r = 0.25).
Impairment of glucose homeostasis may be characterized by elevated fasting glucose or fasting insulin, elevated glucose or insulin at 2 h after oral glucose tolerance test (OGTT), or elevated glycated hemoglobin (HbA 1c ). We tested associations of each of the 17 loci of interest in a subset of MAGIC cohorts with GWAS data informative for these traits. Because HbA 1c is a measure of average glycemia over the preceding 2-3 months, we hypothesized that if an association of these loci with additional traits was present, it should be directionally consistent. The three loci with the largest effect sizes on fasting glucose-G6PC2, MTNR1B and GCK-all showed genome-wide significant and directionally consistent associations with HbA 1c ; DGKB-TMEM195, ADCY5, SLC2A2, PROX1, SLC30A8 and TCF7L2 showed nominal (P < 0.05) evidence of directionally consistent association ( Table 2) . The fasting glucose-raising alleles at TCF7L2, SLC30A8, GCK and ADCY5 were associated (P < 0.0002) with increased 2-h glucose ( Table 2) ; a parallel MAGIC project reports the genome-wide significant association with 2-h glucose of another ADCY5 SNP in strong linkage disequilibrium (LD) with our lead SNP (r 2 = 0.82) 29 . In contrast, and consistent with previous reports that the fasting glucoseraising allele of GCKR is associated with greater insulin release during OGTT 11, 12, 30 , this allele was associated with lower 2-h glucose.
Testing of these loci for association with T2D as a dichotomous trait in up to 40,655 cases and 87,022 nondiabetic controls demonstrated that the fasting glucose-raising alleles at seven loci (in or near ADCY5, PROX1, GCK, GCKR and DGKB-TMEM195 and the known T2D genes TCF7L2 and SLC30A8) are robustly associated (P < 5 × 10 −8 ) with increased risk of T2D ( Table 2) . The association of a highly correlated SNP in ADCY5 with T2D in partially overlapping samples is reported by our companion manuscript 29 . We found less significant T2D associations (P < 5 × 10 −3 ) for variants in or near CRY2, FADS1, GLIS3 and C2CD4B ( Table 2) . These data clearly show that loci with similar fasting glucose effect sizes may have very different T2D risk effects (see, for example, ADCY5 and MADD in Table 2) .
Given that several alleles associated with higher fasting glucose levels were also associated with increased T2D risk and that the T2Drelated genes TCF7L2 and SLC30A8 showed association with fasting glucose, we systematically investigated association of all established T2D loci with the same four fasting diabetes-related quantitative traits. We found directionally consistent nominal associations (P < 0.05) of T2D risk alleles with higher fasting glucose for 11 of 18 established T2D loci, including MTNR1B ( Supplementary Table 3 ). These data demonstrate that a large T2D effect size does not always translate to an equivalently large fasting glucose effect in nondiabetic persons, as clearly highlighted when contrasting the remarkably small effects of TCF7L2 on fasting glucose compared to MTNR1B ( Table 2) .
Impact of new glycemic loci on other metabolic traits
Next, we used available GWAS results for additional metabolic phenotypes (BMI from GIANT 31 , blood pressure from Global BPgen 32 and lipids from ENGAGE 33 ) to assess the impact of the newly discovered glycemic loci on these traits. None of the newly discovered loci had significant (P < 0.01) associations with BMI or blood pressure (Table 3) . Notably, the FADS1 glucose-raising allele was associated with increased total cholesterol (P = 2.5 × 10 −6 ), In each plot, the expected null distribution is plotted along the red diagonal, the entire distribution of observed P values is plotted in black and a distribution that excludes the ten newly discovered loci shown in Figure 1 is plotted in green. For fasting glucose and HOMA-B, the distribution that excludes the four genome-wide significant fasting glucose-associated loci reported previously (in GCK, GCKR, G6PC2 and MTNR1B) is plotted in blue. A comparison of the observed P values for each trait shows that fasting glucose and HOMA-B associations are much more likely to be detected than fasting insulin and HOMA-IR associations.
A r t i c l e s low-density lipoprotein cholesterol (P = 8.5 × 10 −6 ) and highdensity lipoprotein cholesterol (P = 2.9 × 10 −5 ), but was associated with lower triglyceride levels (P = 1.9 × 10 −6 ) ( Table 3) ; a consistent association of this locus with lipid levels has been previously reported 34 . The fasting glucose-associated variant in MADD was not associated with lipid levels and is not in LD (r 2 < 0.1) with a previously reported high-density lipoprotein cholesterol SNP (rs7395662) 33 , suggesting two independent signals within the same locus, one affecting lipid levels and the other affecting fasting glucose levels ( Table 3) .
Potential functional roles of newly discovered loci
We investigated the likely functional role of genes mapping closest to the lead SNPs using several sources of data, including human disease 
Figure 3
Variation in levels of fasting glucose depending on the number of risk alleles at newly identified loci, weighted by effect size in an aggregate genotype score for the Framingham Heart Study. The bar plots show the average and standard error of fasting glucose in mmol/l for each value of the genotype score based on the regression coefficient (right y axis), and the histogram denotes the number of individuals in each genotype score category (left y axis). Comparable results were obtained for the NFBC 1966 and ARIC cohorts. On average, the range spans ~0.4 mmol/l (~7.2 mg/dl) from low to high genotype score. Table 4 ). The newly discovered and previously established glycemic loci represent various biological functions: signal transduction (DGKB-TMEM195, ADCY5, FADS1, ADRA2A, SLC2A2, GCK, GCKR, G6PC2 and IGF1), cell proliferation and development (GLIS3, MADD and PROX1), glucose transport and sensing (SLC2A2, GCK, GCKR and G6PC2) and circadian rhythm regulation (MTNR1B and CRY2). All of these pathways represent further avenues for physiological characterization and possible therapeutic intervention for T2D. However, we note that other genes could be causal (Box 1 and Supplementary Table 4) , and further experimental evidence will be needed to unequivocally link specific genes with phenotypes.
A r t i c l e s databases, evidence from animal models and bioinformatic analyses (see Box 1, Online Methods and Supplementary
Expression analyses
We measured expression of the genes mapping closest to our lead SNPs (in DGKB-TMEM195, ADCY5, MADD, its neighboring gene SLC39A13 (a member of a family of zinc transporters mapping ~45 kb from the MADD lead SNP), ADRA2A, FADS1, CRY2, SLC2A2, GLIS3, PROX1 and C2CD4B) in human pancreas and other metabolically relevant tissues (Supplementary Fig. 4a) . Although there was evidence of expression in human islets for nearly all genes tested (with the sole exception of TMEM195), we found that DGKB and MADD were most strongly expressed in brain, SLC2A2, FADS1, TMEM195 and PROX1 were most strongly expressed in liver and ADCY5 was most strongly expressed in heart, whereas SLC39A13, ADRA2A and CRY2 were broadly expressed. Notably, C2CD4B was highly expressed in the whole pancreas with lower levels in isolated islets, suggesting that it is also present in exocrine cells. A duplicate experiment in a different laboratory obtained similar results (Supplementary Fig. 4b) .
We further examined expression of these transcripts in flow-sorted human beta cells from two separate individuals and documented beta-cell expression for all but TMEM195, with SLC39A13, CRY2, GLIS3 and PROX1 being particularly highly expressed in these cells (Supplementary Fig. 4c ). Expression levels in metabolically relevant tissues for DGKB (beta cells) and TMEM195 (liver) provided equally credible evidence for their respective candidacies as the causal gene at these loci. Furthermore, based on its relatively high expression levels in beta cells, SLC39A13 (neighboring gene to MADD) constitutes a possible candidate gene that may merit further investigation.
Potential causal variants, eQTLs and copy number variants
Our results interrogate only a fraction of the common variants in any given genomic region; we therefore expect that for the majority of the loci here described, the underlying causal variant has yet to be identified. Nevertheless, for some loci there are possible SNP A r t i c l e s candidates; in SLC2A2, the lead SNP (rs11920090) is in perfect LD (r 2 = 1.0) with rs5400 (stage 1 discovery association P = 5.9 × 10 −6 ), which codes for the amino acid substitution T110I, predicted to be "possibly damaging" by PolyPhen 35 and PANTHER (Pdel = 0.92) 36 .
In GCKR, the lead SNP is in strong LD (r 2 = 0.93) with rs1260326, encoding P446L, a nonsynonymous variant previously associated with fasting glucose and HOMA-IR 11, 12, 30 and predicted by PolyPhen to be "probably damaging." A recent functional study has demonstrated that this variant indirectly leads to increased GCK activity, resulting in the observed effects on fasting glucose and triglyceride levels 37 . Both the SLC2A2 T110I and GCKR P446L substitutions were predicted to be "tolerated" by SIFT 38 , highlighting the difficulties in obtaining consensus functional predictions from different informatic approaches. We used publicly available expression quantitative trait locus (eQTL) datasets for liver 39 , cortex 40 and Epstein-Barr virus-transformed lymphoblastoid cell lines 41 to explore additional possible causal mechanisms by testing for association between replicated loci and mRNA expression levels of nearby genes (Online Methods). The lead SNP in FADS1, rs174550, is in strong LD with (r 2 = 0.80) and is in close proximity (130 bp) to rs174548, a SNP highly associated with FADS1 mRNA expression levels in liver (P = 1.7 × 10 −5 ) and with FADS2 mRNA expression levels in lymphoblastoid cells (P = 3.1 × 10 −4 ). The SNP rs174548 has also been associated (up to P = 4.5 × 10 −8 ) with a number of serum glycerophospholipid concentrations in a GWAS investigating metabolomic profiles 42 , and rs174550 also showed strong associations (P < 5.2 × 10 −7 ) with the same metabolites (data not shown). These results are substantiated by previous work associating SNPs in this region with the fatty acid composition of phospholipids 43 . The latter data suggest that the minor allele variant of rs174550 results in a reduced efficiency of the fatty acid delta-5 desaturase reaction 42 . Finally, bioinformatic analysis identifies a perfect proxy, rs174545 (r 2 = 1.0 with rs174550), whose glucoseraising allele abolishes a predicted target site for the miR-124 microRNA (see Online Methods). Taken together, these data support the hypothesis that not only the abundance of fatty acids, but also their precise composition and degree of desaturation, may influence glucose homeostasis.
Although our study was not designed to explicitly investigate the impact of copy number variation on glycemic traits, we took advantage of existing data 44 to investigate whether any of our lead SNPs are
Box 1: Genes nearest to loci associated with fasting diabetes-related quantitative traits
The DGKB-TMEM195 locus was recently reported to be associated with fasting glucose 24 ; here we report genome-wide significant replication of that finding and evaluate the genes mapping closest to the lead SNP in further detail. DGKB encodes the β (1 of 10) isotype of the catalytic domain of diacylglycerol kinase, which regulates the intracellular concentration of the second messenger diacylglycerol. In rat pancreatic islets, glucose increases diacylglycerol 49 , which activates protein kinase C (PKC) and thus potentiates insulin secretion 50 . TMEM195 encodes transmembrane protein 195, an integral membrane phosphoprotein highly expressed in liver.
ADCY5 encodes adenylate cyclase 5, which catalyzes the generation of cAMP. Upon binding to its receptor in pancreatic beta cells, glucagon-like peptide 1 (GLP-1) induces cAMP-mediated activation of protein kinase A, transcription of the proinsulin gene and stimulation of insulin secretory processes 51 .
MADD encodes mitogen-activated protein kinase (MAPK) activating death domain, an adaptor protein that interacts with the tumor necrosis factor α receptor to activate MAPK. Both PKC and MAPK have been implicated in the proliferation of beta cells induced by GLP-1 (ref. 51 ), suggesting that DGKB and MADD may contribute to beta-cell mass and insulin secretion in this manner as well. Also in this region, SLC39A13 encodes a putative zinc transporter required for connective tissue development and BMP/TGF-β signaling 52 . NR1H3 encodes the liver X receptor alpha (LXRA) protein, which contains the retinoid response element.
Glucose stimulates the transcriptional activity of LXR, which acts as a molecular switch that integrates hepatic glucose metabolism and fatty acid synthesis 53 .
ADRA2A encodes the α 2A adrenergic receptor, which is expressed in beta cells and whose activation leads to an outward potassium current independent of the islet potassium-sensitive ATP (K ATP ) channel, thus possibly modifying insulin release 54 . Mice with null mutations display abnormal glucose homeostasis in addition to cardiac hypertrophy and abnormal heart rate and blood pressure.
FADS1 encodes fatty acid desaturase 1, which catalyzes the biosynthesis of highly unsaturated fatty acids from precursor essential polyunsaturated fatty acids.
One such product is arachidonic acid; in rodent beta cells, arachidonic acid liberated by phospholipase A 2 augments glucose-mediated insulin release 55 . Two other members of the same family, FADS2 and FADS3, also reside in this region. By directing fatty acids down this metabolic pathway, increased activity of these enzymes may lower circulating triglyceride concentrations.
CRY2 encodes cryptochrome 2, an integral component of the mammalian circadian pacemaker 56 . Mice with null mutations in this gene present with abnormal circadian rhythmicity and several metabolic abnormalities including impaired glucose tolerance, increased insulin sensitivity, decreased body weight and adipose tissue, and abnormal heart rate. Together with MTNR1B [15] [16] [17] , this is the second circadian gene associated with fasting glucose in humans, contributing further evidence to the emerging idea that this pathway regulates glucose homeostasis 57 . In the same region, MAPK8IP1 encodes the scaffolding protein JIP1. Cross-talk between JIP1 and JIP3 has been implicated in the regulation of ASK1-SEK1-JNK signaling during glucose deprivation 58 . A missense mutation in this gene (leading to a S59N amino acid substitution) segregates with diabetes in one family affected with a Mendelian form of the disease 59 .
SLC2A2 encodes the GLUT2 transporter responsible for transporting glucose into beta cells and triggering the glucose-mediated insulin secretion cascade. In humans, recessive mutations in this gene lead to Fanconi-Bickel syndrome, a rare disorder characterized by hepatorenal glycogen accumulation, proximal renal tubular dysfunction and impaired utilization of glucose and galactose 60 ; mouse mutants also show hyperglycemia and abnormal glucose homeostasis 61 .
GLIS3 encodes the transcription factor GLIS family zinc finger 3 isoform, a Krüppel-like zinc finger protein that both activates and represses transcription and participates in beta-cell ontogeny 62, 63 . Functional mutations in this gene cause a syndrome of neonatal diabetes and congenital hypothyroidism 63 . Polymorphisms within this gene have recently been associated with type 1 diabetes risk (t1dgc.org).
PROX1 encodes the prospero homeobox protein 1, a novel co-repressor of hepatocyte nuclear factor 4α 64 that plays a crucial role in beta-cell development; mutations in its target gene HNF4A cause maturity-onset diabetes of the young, type 1 (ref. 65) .
C2CD4B (formerly FAM148B) encodes the nuclear localized factor 2 (NLF2). It is expressed in endothelial cells and upregulated by proinflammatory cytokines 66 .
As shown here, it has a high level of expression in the pancreas, although its putative molecular connection with glucose homeostasis is presently unclear.
IGF1 encodes the insulin-like growth factor 1 and is the sole genome-wide significant locus associated with HOMA-IR in our study. Humans and mice null for IGF1 display abnormal glucose homeostasis, with insulin resistance, increased circulating insulin and insensitivity to growth hormone 67 .
A r t i c l e s in LD with common, diallelic copy number polymorphisms (CNPs) mapping within a 1-Mb window. Of the fasting glucose loci, only DGKB-TMEM195 has a validated, common CNP affecting sequence within 1 Mb of the index SNP 44 . Despite the proximity of this CNP to the associated SNP (~25 kb), the CNP is essentially uncorrelated with the index SNP (r 2 = 0.01 in HapMap CEU) and is therefore unlikely to explain the observed association with fasting glucose level.
DISCUSSION
In this meta-analysis of 21 stage 1 discovery GWAS cohorts followed by targeted stage 2 replication of 25 loci in 33 additional cohorts (totaling up to 122,743 nondiabetic participants), we report new genomewide significant associations of SNPs in or near ADCY5, MADD, ADRA2A, CRY2, FADS1, GLIS3, SLC2A2, PROX1 and C2CD4B with fasting glucose and one SNP near IGF1 associated with fasting insulin and HOMA-IR. We have also confirmed associations of variants in GCK, GCKR, G6PC2 and MTNR1B with fasting glucose and achieved genome-wide significance for the recently reported DGKB-TMEM195 locus 24 and for variants in the known T2D-associated genes TCF7L2 and SLC30A8. All of the fasting glucose-associated SNPs showed consistent nominal associations with HOMA-B, and those in GCK, G6PC2, MTNR1B, DGKB-TMEM195, ADCY5, FADS1 and GLIS3 did so at genome-wide significant levels. As previously reported 11, 12, 30 , GCKR is also associated with fasting insulin and HOMA-IR.
Notably, in addition to the established T2D-associated loci in TCF7L2, SLC30A8 and MTNR1B, five of the loci that are associated with elevated fasting glucose levels in nondiabetic individuals (in ADCY5, GCK, GCKR, PROX1 and DGKB-TMEM195) also increase the risk of T2D in separate T2D case-control studies. However, this overlap is incomplete and highlights the fact that the magnitude of the effect on fasting glucose is not predictive of the effect on T2D risk, as shown when comparing fasting glucose and T2D effect sizes for MTNR1B and TCF7L2, or for ADCY5 and MADD ( Table 2) . Loci on the latter two genes have similar effect sizes on fasting glucose and have similar allele frequencies, and yet the former is robustly associated with T2D risk (OR 1.12, P = 5.5 × 10 −21 ) whereas the latter is not (OR 1.01, P = 0.3) in the same samples. This suggests that not all loci associated with fasting glucose within the 'physiological' range are also associated with 'pathological' fasting glucose levels and T2D risk. Thus, variation in fasting glucose in healthy individuals is not necessarily an endophenotype for T2D, which posits the hypothesis that the mechanism by which glucose is raised, rather than a mere elevation in fasting glucose levels, is a key contributor to disease progression. On the other hand, we cannot rule out the existence of separate T2D-protective variants within loci for which elevated fasting glucose does not progress to manifest T2D; we also cannot rule out the effect of cohort selection in the detection of the loci with variable effects on fasting glucose and T2D risk. Nevertheless, this work shows that targeting quantitative traits in GWAS searches can help identify genetic determinants of overt disease.
With regard to insulin resistance, our analyses resulted in only one new genome-wide significant locus associated with fasting insulin and HOMA-IR. The associated SNP rs35767 is 1.2 kb upstream of IGF1, raising the possibility that it may influence IGF1 expression levels (we have found no direct support for this notion in the limited eQTL data available). Although not reaching genome-wide significance, we note that SNP rs4675095 in IRS1 (the insulin receptor substrate-1 gene) was also associated with HOMA-IR (P = 4.6 × 10 −3 ), which, given IRS1's excellent biological credentials, will warrant further investigation. This SNP is not in LD with the widely studied missense SNP substitution G972R (rs1801278), nor is it in LD with the newly discovered T2D SNP rs2943641 (ref. 45 ), whose C risk allele was only nominally associated with increased fasting insulin (P = 0.02) and HOMA-IR (P = 0.04) in our discovery dataset. The previously reported associations of SNPs in PANK1 with fasting insulin 24 did not receive strong support in our discovery cohorts (P = 0.04 and P = 0.17 for rs11185790 and rs1075374, respectively).
Notably, our large-scale meta-analyses produced more than a dozen robust associations with fasting glucose and only two with fasting insulin and HOMA-IR (GCKR and IGF1). Although the somewhat smaller sample size for the insulin analysis may have contributed to this discrepancy, a comparison of the similarly powered HOMA-B and HOMA-IR analyses reveals associations with HOMA-B several orders of magnitude more significant than those seen with HOMA-IR (Fig. 2) . Because insulin itself is a component of the numerator in both measures, one cannot attribute this discrepancy to technical differences in insulin measurements across cohorts. Similarly, because the quantile-quantile plots are very similar for fasting insulin and HOMA-IR, we do not believe that the use of a mathematical formula (as was used with HOMA-IR) rather than a direct measurement (as was used with fasting insulin) has affected our analyses substantially. HOMA-B and HOMA-IR have comparable heritability estimates (0.26 and 0.27 in the Framingham Heart Study, respectively), and their correlation is substantial (r = 0.55 in the Framingham Heart Study). Thus, not only may there be a difference in the identity of specific genetic determinants for each trait 46 , but the genetic architecture may be distinct for each trait, with more modest effects, fewer loci, rarer variants, or a stronger environmental modification underlying HOMA-IR. In addition, HOMA-IR (which is composed of fasting values) is an imperfect estimate of global insulin resistance, as it addresses mostly hepatic sensitivity to insulin and is partially affected by beta-cell function. The heritability of HOMA-IR is lower than the heritability for insulin sensitivity derived from the minimal model 47 . Exploration of gene × environment interactions and analysis of datasets that include 2-h glucose and insulin values may reveal other genetic factors that increase insulin resistance in humans 29 .
In conclusion, our large-scale meta-analysis of GWAS has identified ten new loci associated with glycemic traits whose in-depth physiological investigation should further our understanding of glucose homeostasis in humans and may reveal new pathways for diabetes therapeutics.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website. e r r at u m Erratum: New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk
